Evidence map›Paper›PMID 29862044›Full record

ArticleRMD open2018

Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project.

Marian H van Beers-Tas, Marieke M Ter Wee, Lilian H van Tuyl, Bertha Maat, Wijnanda Hoogland, Aase H Hensvold, Anca I Catrina, Erika Mosor, Tanja A Stamm, Axel Finckh and 6 more

Open access · goldAbstract read
In one paragraph

Article in RMD open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 5 countries.

Marian H van Beers-TasAmsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.
Marieke M Ter WeeAmsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands.
Lilian H van TuylAmsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands.
Bertha MaatAmsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.
Wijnanda HooglandAmsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.
Aase H HensvoldKarolinska University Hospital, Stockholm, Sweden.
Anca I CatrinaKarolinska University Hospital, Stockholm, Sweden.
Erika MosorSection for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Tanja A StammSection for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3073-7284
Axel FinckhDivision of Rheumatology, University Hospital of Geneva, Geneva, Switzerland.
Delphine S CourvoisierDivision of Rheumatology, University Hospital of Geneva, Geneva, Switzerland.
Andrew FilerUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Ilfita SahbudinUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Rebecca J StackDepartment of Psychology, Nottingham Trent University, Nottingham, UK.
Karim RazaDepartment of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
Dirkjan van SchaardenburgAmsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.
Amsterdam UMC Location University of Amsterdam · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLKarolinska University Hospital · SEReade · NLStatistics Austria · ATUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Geneva · CHNottingham Trent University · GBSandwell & West Birmingham Hospitals NHS Trust · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectivesTo describe the development and assess the psychometric properties of the novel 'Symptoms in Persons At Risk of Rheumatoid Arthritis' (SPARRA) questionnaire in individuals at risk of rheumatoid arthritis (RA) and to quantify their symptoms.

methodsThe questionnaire items were derived from a qualitative study in patients with seropositive arthralgia. The questionnaire was administered to 219 individuals at risk of RA on the basis of symptoms or autoantibody positivity: 74% rheumatoid factor and/or anticitrullinated protein antibodies positive, 26% seronegative. Validity, reliability and responsiveness were assessed. Eighteen first degree relatives (FDR) of patients with RA were used for comparison.

resultsFace and content validity were high. The test-retest showed good agreement and reliability (1 week and 6 months). Overall, construct validity was low to moderate, with higher values for concurrent validity, suggesting that some questions reflect symptom content not captured with regular Visual Analogue Scale pain/well-being. Responsiveness was low (small subgroup). Finally, the burden of symptoms in both seronegative and seropositive at risk individuals was high, with pain, stiffness and fatigue being the most common ones with a major impact on daily functioning. The FDR cohort (mostly healthy individuals) showed a lower burden of symptoms; however, the distribution of symptoms was similar.

conclusionsThe SPARRA questionnaire has good psychometric properties and can add information to currently available clinical measures in individuals at risk of RA. The studied group had a high burden and impact of symptoms. Future studies should evaluate whether SPARRA data can improve the prediction of RA in at risk individuals.

Indexed as

patient perspectivequalitative researchrheumatoid arthritis

Identifiers

PMID29862044
PMCPMC5976102
OpenAlexW2804930552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.